Clinical Trials on Childhood Chronic Immune Thrombocytopenia in Hungary

Total 96 results

argenx
Quintiles, Inc.

Completed

A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With ITP

Primary Immune Thrombocytopenia

Austria, Belgium, France, Germany, Spain, Czechia, Hungary, Poland, Ukraine, United Kingdom
Pfizer

Recruiting

Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia

Primary Immune Thrombocytopenia

United States, Australia, Canada, Czechia, Poland, Hungary, United Kingdom
UCB Biopharma SRL

Terminated

A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) (myOpportunITy3)

Primary Immune Thrombocytopenia

United States, China, Georgia, Germany, Hungary, Italy, Japan, Moldova, Republic of, Poland, Russian Federation, Spain, Taiwan, Ukraine, United Kingdom
Baxalta now part of Shire

Completed

Efficacy and Safety Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Adult Subjects With Chronic Idiopathic Thrombocytopenic Purpura

Immune Thrombocytopenic Purpura (ITP)

Poland, Hungary, Germany, Czechia
Biotest
Syneos Health

Completed

This Clinical Study is to Test Efficacy and Safety of BT595 in Chronic Primary Immune Thrombocytopenia (ITP)

Immune Thrombocytopenia

Bulgaria, Czechia, Germany, Hungary, Serbia, Spain
UCB Biopharma SRL

Terminated

A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) (myOpportunITy1)

Primary Immune Thrombocytopenia

United States, Bulgaria, France, Georgia, Greece, Hungary, Italy, Japan, Korea, Republic of, Moldova, Republic of, Poland, Romania, Russian Federation, Taiwan, Ukraine, United Kingdom
Novartis Pharmaceuticals

Recruiting

Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP) (VAYHIT1)

Primary Immune Thrombocytopenia (ITP)

China, United States, Spain, Singapore, Austria, Germany, Belgium, Italy, Japan, Czechia, Hong Kong, Hungary, Malaysia, Argentina, Bulgaria, Turkey, Vietnam, Australia, Thailand, Mexico, United Kingdom, France, Romania, Norway, India
argenx

Active, not recruiting

A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). (ADVANCE+)

Primary Immune Thrombocytopenia

United States, Austria, Belgium, Bulgaria, Czechia, France, Georgia, Germany, Hungary, Italy, Japan, Netherlands, Poland, Russian Federation, Spain, Turkey, United Kingdom, Ukraine
GlaxoSmithKline

Completed

A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Purpura, Thrombocytopaenic, Idiopathic

Italy, Germany, Hong Kong, Korea, Republic of, United States, Pakistan, Russian Federation, India, Czech Republic, Hungary, France
Momenta Pharmaceuticals, Inc.

Terminated

Safety and Tolerability of M254 in Healthy Volunteers and Immune Thrombocytopenic Purpura (ITP) Patients

Immune Thrombocytopenic Purpura (ITP)

United States, Poland, Hungary, Netherlands, Italy, Spain, Belgium
Novartis Pharmaceuticals

Recruiting

A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids (VAYHIT2)

Primary Immune Thrombocytopenia

United States, China, Germany, Spain, Singapore, Japan, Taiwan, Belgium, Italy, Czechia, Hungary, Malaysia, Korea, Republic of, Turkey, Argentina, Thailand, India, United Kingdom, France, Australia, Romania, Austria, Norway, Netherlands, Philippin...
argenx

Completed

A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). (ADVANCE)

Primary Immune Thrombocytopenia

United States, Austria, Belgium, Bulgaria, Czechia, France, Georgia, Germany, Hungary, Italy, Japan, Netherlands, Poland, Russian Federation, Spain, Turkey, Ukraine, United Kingdom
GlaxoSmithKline

Completed

LENS - Long-term Eltrombopag Observational Study (LENS)

Purpura, Thrombocytopaenic, Idiopathic

United States, Bulgaria, Italy, Peru, Russian Federation, Canada, France, Germany, Hong Kong, Spain, Sweden, United Kingdom, Hungary, Poland, Ukraine, Czech Republic, India, Australia, Tunisia, Puerto Rico, Pakistan
Sobi, Inc.

Active, not recruiting

Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months

Immune Thrombocytopenia

United States, France, Germany, Hungary, Poland, Russian Federation, Turkey, Ukraine, United Kingdom
Amgen

Completed

Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)

Immune Thrombocytopenia

United States, Canada, Belgium, Czechia, Mexico, Turkey, Australia, Spain, France, Israel, Hungary, South Africa, Poland, Russian Federation, United Kingdom, Brazil, Switzerland
Sanofi

Completed

Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)

Acquired Thrombotic Thrombocytopenic Purpura

United States, Austria, Belgium, Canada, Czechia, France, Hungary, Israel, Italy, Spain, Switzerland, Turkey, United Kingdom
Rigel Pharmaceuticals

Completed

A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) (FIT)

Immune Thrombocytopenic Purpura

United States, Australia, United Kingdom, Canada, Italy, Denmark, Hungary, Netherlands
Rigel Pharmaceuticals

Completed

Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

Immune Thrombocytopenic Purpura

Spain, United States, Australia, Poland, United Kingdom, Canada, Czechia, Bulgaria, Romania, Austria, Denmark, Hungary, Italy, Netherlands, Norway
Principia Biopharma, a Sanofi Company

Recruiting

Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) (LUNA 3)

Immune Thrombocytopenia

United States, China, Argentina, Australia, Brazil, Canada, France, Hungary, Israel, Korea, Republic of, Mexico, Russian Federation, Singapore, Spain, Thailand, United Kingdom, Austria, Chile, Germany, Italy, Japan, Netherlands, Norway and more
Ablynx, a Sanofi company

Completed

Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura (HERCULES)

Acquired Thrombotic Thrombocytopenic Purpura

United States, Australia, Austria, Belgium, Canada, Czechia, France, Germany, Hungary, Israel, Italy, Netherlands, Spain, Switzerland, Turkey, United Kingdom
Semmelweis University

Terminated

The Effect of 25-OH-Vitamin-D3 Substitution in Patients With Malignant and Immune-hematologic Diseases (D-HEM)

Chronic Lymphoid Leukemia

Hungary
Somogy Megyei Kaposi Mór Teaching Hospital

Completed

Follow-up Study of the Effectiveness of Virtual Reality Therapy in MS Patients

Multiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Primary Progressive

Hungary
Somogy Megyei Kaposi Mór Teaching Hospital
University Medical Center Groningen

Completed

The Effect of Neurorehabilitation Therapy on Postural Control, Mobility and Quality of Life in Multiple Sclerosis Patients

Multiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Primary Progressive

Hungary
Hoffmann-La Roche

Completed

An Observational Study Examining the Effect of Added MabThera Therapy in Patients With Untreated Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Hungary
Amgen

Active, not recruiting

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer (RECITE)

Chemotherapy-induced Thrombocytopenia

United States, France, Austria, Hungary, Russian Federation, Romania, Spain, Turkey, Greece, Italy, Bulgaria, Canada, Portugal, Argentina, Poland, Mexico, Colombia, Peru, Brazil, Ukraine
European Organisation for Research and Treatment...

Unknown

Chlorambucil in Treating Patients With Advanced Chronic Lymphocytic Leukemia

Leukemia

Belgium, Netherlands, Czech Republic, Hungary, Italy, Macedonia, The Former Yugoslav Republic of, Portugal
Novartis Pharmaceuticals

Completed

Study to Investigate the Efficacy and Safety of QGE031 in Adolescent Patients With Chronic Spontaneous Urticaria (CSU)

Chronic Spontaneous Urticaria

Taiwan, Turkey, Belgium, Spain, Germany, India, Argentina, Canada, Russian Federation, Hungary
Novartis Pharmaceuticals

Terminated

Study of Efficacy and Safety of Ligelizumab in Adolescents and Adults With Chronic Inducible Urticaria Who Remain Symptomatic Despite Treatment With H1- Antihistamines (PEARL-PROVOKE)

Chronic Inducible Urticaria

Taiwan, Turkey, United States, Australia, Hungary, Spain, Greece, Russian Federation, Slovakia
Octapharma

Completed

Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy (CIDP)

Chronic Inflammatory Demyelinating Poly(Radiculo)Neuropathy

Canada, Poland, Romania, Ukraine, Bulgaria, Czechia, Germany, Hungary, Russian Federation
Mallinckrodt
Parexel

Completed

Extracorporeal Photopheresis (ECP) With Methoxsalen for Chronic Graft Versus Host Disease (cGVHD)

Chronic Graft Versus Host Disease

United States, France, Germany, United Kingdom, Spain, Italy, Austria, Hungary
Celldex Therapeutics

Active, not recruiting

A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

Chronic Spontaneous Urticaria

Spain, United States, Poland, Georgia, South Africa, Bulgaria, Hungary, Estonia, Germany
AstraZeneca

Active, not recruiting

A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (MAJIC)

Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Spain, United States, Australia, France, Czechia, Hungary, Poland
Celldex Therapeutics

Active, not recruiting

A Study of CDX-0159 in Patients With Chronic Inducible Urticaria

Chronic Inducible Urticaria

United States, Latvia, Spain, Poland, Georgia, South Africa, Germany, Lithuania, Estonia, Hungary, Bulgaria
Janssen-Cilag International NV

Completed

Telaprevir Open-Label Study in Co-Infected Patients

Hepatitis C, Chronic

United Kingdom, Belgium, Germany, Portugal, Russian Federation, Hungary, Ireland, Luxembourg
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma

Chronic Lymphocytic Leukaemia (CLL) | Multiple Myeloma (MM) | B-Cell Non-Hodgkin Lymphoma (NHL)

France, Australia, Germany, Korea, Republic of, United Kingdom, Hungary, Poland, Singapore
Novartis Pharmaceuticals

Completed

An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of LOU064 in Subjects With CSU

Chronic Spontaneous Urticaria

United States, Belgium, United Kingdom, Hungary, Spain, France, Turkey, Canada, Czechia, Russian Federation, Poland, Japan, Argentina, Denmark, Slovakia
AbbVie

Completed

A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent). (VENICE II)

Chronic Lymphocytic Leukemia (CLL)

Argentina, Australia, Bulgaria, Hong Kong, Hungary, Mexico, New Zealand, Poland, Russian Federation, Taiwan
University Hospital Muenster
Deutsche Krebshilfe e.V., Bonn (Germany)

Recruiting

International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma (LBL 2018)

Lymphoblastic Lymphoma, Childhood

Spain, Austria, Denmark, Finland, Germany, Belgium, Switzerland, China, Czechia, France, Hungary, Ireland, Israel, Italy, Netherlands, Norway, Poland, Portugal, Russian Federation, Slovakia, Sweden
Novartis Pharmaceuticals

Recruiting

A Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo and With Omalizumab as Active Control in CSU Adult Patients.

Chronic Spontaneous Urticaria

Switzerland, Australia, Italy, Spain, France, Germany, Korea, Republic of, Netherlands, Taiwan, India, Czechia, Hungary, Thailand, Turkey, Malaysia, Canada, Argentina, Bulgaria, Slovakia, Brazil, Poland
Novartis Pharmaceuticals

Recruiting

An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib

Chronic Spontaneous Urticaria

United States, Korea, Republic of, Spain, France, Germany, Bulgaria, United Kingdom, China, Hungary, Czechia, Turkey, Argentina, Colombia, Italy, Denmark, Japan, Taiwan, Australia, Singapore, Switzerland, Russian Federation, Thailand and more
Gilead Sciences

Terminated

Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion

B-cell Chronic Lymphocytic Leukemia (CLL) With 17p Deletion

United States, Spain, Denmark, Belgium, Australia, Poland, Romania, Czechia, Italy, France, Hungary, Austria, Portugal, United Kingdom
Sanofi
Regeneron Pharmaceuticals

Active, not recruiting

Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)

Chronic Spontaneous Urticaria

China, France, Spain, Argentina, Germany, Japan, United States, Canada, Hungary, Russian Federation, United Kingdom
Novartis Pharmaceuticals

Completed

A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines (REMIX-1)

Chronic Spontaneous Urticaria

United States, Hungary, Taiwan, Spain, Italy, Korea, Republic of, Australia, France, Bulgaria, Czechia, Turkey, India, Argentina, Mexico, Japan, Colombia, Russian Federation, Puerto Rico, Singapore
Novartis Pharmaceuticals

Completed

This Was a Dose-finding Study to Evaluate Efficacy and Safety of LOU064 in Patients With CSU Inadequately Controlled by H1-antihistamines

Chronic Spontaneous Urticaria

United States, Belgium, United Kingdom, Germany, Hungary, Spain, France, Turkey, Canada, Czechia, Netherlands, Poland, Japan, Russian Federation, Argentina, Denmark, Slovakia
Gustave Roussy, Cancer Campus, Grand Paris
Children's Oncology Group

Unknown

Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients

B-cell Non Hodgkin Lymphoma | Mature B-cell Leukemia Burkitt-type

Belgium, France, United Kingdom, Netherlands, Canada, Hungary, Italy, Poland, Spain, China
Novartis Pharmaceuticals

Completed

A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines

Chronic Spontaneous Urticaria

United States, Croatia, Hungary, India, Malaysia, Spain, Germany, Austria, Czechia, Denmark, France, Korea, Republic of, Greece, Singapore, Thailand, Bulgaria, Argentina, Turkey, Guatemala, Brazil, Russian Federation, Peru, Canada, Sw... and more
Sun Pharma Advanced Research Company Limited

Active, not recruiting

Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

Healthy (For Part A) | Chronic Myeloid Leukemia (for Part B and C)

United States, Spain, Hungary, Italy, India, Belgium, France, Romania, Singapore, United Kingdom, Korea, Republic of, Turkey
Telios Pharma, Inc.

Active, not recruiting

Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Relapsed/Refractory B Cell Malignancies | Mantle Cell Lymphoma and Diffuse Large B Cell Lymphoma | Treatment-Naive B Cell Malignancies

United States, Poland, Ukraine, Hungary, Italy, Russian Federation, United Kingdom
Bristol-Myers Squibb

Withdrawn

Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL

Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia

Netherlands, Italy, United Kingdom, Russian Federation, Poland, Hungary
Novartis Pharmaceuticals

Terminated

Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab

Chronic Spontaneous Urticaria

United States, Spain, Belgium, Croatia, Germany, Hungary, India, Malaysia, Russian Federation, Taiwan, Turkey, Netherlands, Italy, Australia, Israel, Korea, Republic of, Lebanon, Greece, Singapore, Slovakia, Thailand, Austria, Bulgaria and more

Clinical Trials on Childhood Chronic Immune Thrombocytopenia in Hungary

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mexico

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations